Literature DB >> 26677772

Indicators of iron status are correlated with adiponectin expression in adipose tissue of patients with morbid obesity.

F Pihan-Le Bars1, F Bonnet2, O Loréal3, A-G Le Loupp4, M Ropert5, E Letessier6, X Prieur7, K Bach4, Y Deugnier8, B Fromenty9, B Cariou10.   

Abstract

AIM: The aim of this study was to assess interactions between glucose and iron homoeostasis in the adipose tissue (AT) of obese subjects.
METHODS: A total of 46 obese patients eligible for bariatric surgery were recruited into the study. Anthropometric and biochemical characteristics were assessed, and biopsies of subcutaneous (SCAT) and visceral adipose tissue (VAT) performed. The mRNA levels of genes involved in iron and glucose homoeostasis were measured in their AT and compared with a pool of control samples.
RESULTS: Gene expression of hepcidin (HAMP) was significantly increased in the SCAT and VAT of obese patients, while transferrin receptor (TFRC) expression was reduced, compared with non-obese controls, suggesting a higher iron load in obese patients. Also, mRNA levels of adiponectin (ADIPOQ) were decreased in both SCAT and VAT in obese patients, and correlated negatively with hepcidin expression, while adiponectin expression was positively correlated with TFRC expression in both SCAT and VAT. Interestingly, TFRC expression in VAT correlated negatively with several metabolic parameters, such as fasting blood glucose and LDL cholesterol.
CONCLUSION: Iron content appears to be increased in the SCAT and VAT of obese patients, and negatively correlated with adiponectin expression, which could be contributing to insulin resistance and the metabolic complications of obesity.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adiponectin; Adipose tissue; Hepcidin; Insulin resistance; Iron; Obesity

Mesh:

Substances:

Year:  2015        PMID: 26677772     DOI: 10.1016/j.diabet.2015.10.007

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  6 in total

1.  Serum Ferritin Levels Are Associated with Adipose Tissue Dysfunction-Related Indices in Obese Adults.

Authors:  Xiaoyu Ding; Nannan Bian; Jiaxuan Wang; Xiaona Chang; Yu An; Guang Wang; Jia Liu
Journal:  Biol Trace Elem Res       Date:  2022-03-17       Impact factor: 3.738

2.  Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease.

Authors:  Laurence Britton; Kim Bridle; Janske Reiling; Nishreen Santrampurwala; Leesa Wockner; Helena Ching; Katherine Stuart; V Nathan Subramaniam; Gary Jeffrey; Tim St Pierre; Michael House; Joel Gummer; Robert Trengove; John Olynyk; Darrell Crawford; Leon Adams
Journal:  Hepatol Commun       Date:  2018-04-27

3.  Iron Status in Elderly Women Impacts Myostatin, Adiponectin and Osteocalcin Levels Induced by Nordic Walking Training.

Authors:  Jakub Kortas; Ewa Ziemann; Dariusz Juszczak; Katarzyna Micielska; Marta Kozłowska; Katarzyna Prusik; Krzysztof Prusik; Jedrzej Antosiewicz
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

4.  Serum hepcidin and iron status parameters in pregnant women and the association with adverse maternal and fetal outcomes: a study protocol for a prospective cohort study.

Authors:  Gabriela Amstad Bencaiova; Deborah Ruth Vogt; Irene Hoesli
Journal:  BMJ Open       Date:  2019-11-06       Impact factor: 2.692

Review 5.  Iron and non-alcoholic fatty liver disease.

Authors:  Laurence J Britton; V Nathan Subramaniam; Darrell Hg Crawford
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

6.  Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet.

Authors:  Laurence Britton; Lesley-Anne Jaskowski; Kim Bridle; Eriza Secondes; Daniel Wallace; Nishreen Santrampurwala; Janske Reiling; Gregory Miller; Salvatore Mangiafico; Sofianos Andrikopoulos; V Nathan Subramaniam; Darrell Crawford
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.